Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer

New England Journal of Medicine 2026

View at publisher
Authors: Brian M. Wolpin, Wungki Park, Ignacio Garrido-Laguna, A Spira, Alexander Starodub, David Sommerhalder, Salman R. Punekar, Minal Barve, Meredith Pelster, Benjamin Herzberg, Nilofer S. Azad, J. Randolph Hecht
+8 more Sai Hong Ignatius Ou, Tong Lin, Sumit Kar, Lin Tao, Rashmi Vora, Aparna Hegde, Kyaw Aung, David S. Hong
DOI: 10.1056/nejmoa2505783
Cited by: 59
References: 35

Abstract

BACKGROUND: mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate-bound mutant and wild-type RAS. METHODS: -mutated PDAC. RESULTS: G12, G13, or Q61 mutations, 29% (95% CI, 15 to 46) had an objective response. The median duration of response was 8.2 months (95% CI, 3.8 to 8.8), with median values of 8.1 months for progression-free survival and 15.6 months for overall survival. CONCLUSIONS: -mutated PDAC; antitumor activity was also reported. (Funded by Revolution Medicines; RMC-6236-001 ClinicalTrials.gov number, NCT05379985.).

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances Peptidase Inhibition and Analysis

Publication details

Journal / source
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Volume
394
Issue
18
Pages
1790–1802
Publication date
6 May 2026
Language
EN